Dr. Jennifer Brown on Duvelisib in CLL

Jennifer Brown, MD, PhD
Published: Monday, Nov 23, 2015



Jennifer R. Brown, MD, PhD, director, Chronic Lymphocytic Leukemia Center Senior Physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses duvelisib for the treatment of chronic lymphocytic leukemia (CLL).

PI3 kinase inhibitor duvelisib is different from idelalisib because it inhibits the gamma isoform, which is expressed in CLL cells. The advantages of this are unclear; however, it is possible that inhibiting the gamma isoform could lead to enhanced efficacy, says Brown. It could also increase toxicity, she adds.

Data regarding duvelisib are promising, says Brown. At the follow-up of the phase I study, about 66% of patients were still in remission after 2 years. The drug is now in registration trials.
 


Jennifer R. Brown, MD, PhD, director, Chronic Lymphocytic Leukemia Center Senior Physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses duvelisib for the treatment of chronic lymphocytic leukemia (CLL).

PI3 kinase inhibitor duvelisib is different from idelalisib because it inhibits the gamma isoform, which is expressed in CLL cells. The advantages of this are unclear; however, it is possible that inhibiting the gamma isoform could lead to enhanced efficacy, says Brown. It could also increase toxicity, she adds.

Data regarding duvelisib are promising, says Brown. At the follow-up of the phase I study, about 66% of patients were still in remission after 2 years. The drug is now in registration trials.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x